PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate (PII S3i)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03222128 |
Recruitment Status :
Active, not recruiting
First Posted : July 19, 2017
Results First Posted : August 14, 2018
Last Update Posted : November 30, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Symptomatic Severe Aortic Stenosis | Device: TAVR | Not Applicable |
This study design consists of PIIS3i cohort.
The PIIS3i cohort is a single arm non-randomized, historical-controlled study. Patients recruited to the treatment arm will receive an Edwards SAPIEN 3 THV with either transfemoral, transapical or transaortic delivery access.
To ensure that patients are of "intermediate" risk, an STS score of 4 - 8% has been selected.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1074 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Edwards SAPIEN 3 Transcatheter Heart Valve Therapy for Intermediate Risk Patients |
Actual Study Start Date : | February 17, 2014 |
Actual Primary Completion Date : | November 18, 2015 |
Estimated Study Completion Date : | November 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: PIIS3i - SAPIEN 3
PIIS3i - SAPIEN 3 is Operable Group
|
Device: TAVR
Implantation of the SAPIEN 3 |
- Number of Participants With Composite of All-cause Death, All Stroke and Aortic Insufficiency (AI) ≥ Moderate [ Time Frame: 1 year ]
- Composite of All-cause Death, All Stroke, Life Threatening (Disabling)/ Major Bleeding and Major Vascular Complication at 30 Days [ Time Frame: 30 Days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Patient has senile degenerative aortic valve stenosis with echocardiographically derived criteria: mean gradient >40 mmHg or jet velocity greater than 4.0 m/s and an initial aortic valve area (AVA) of <0.8 cm2 or indexed EOA < 0.5 cm2/m2 Qualifying echo must be within 60 days of the date of the procedure.
- Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class II or greater.
- The heart team agrees (and verified in the case review process) that valve implantation will likely benefit the patient.
- The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
- The study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which will be conducted as a phone follow-up.
Exclusion Criteria:
- Heart team assessment of inoperability (including examining cardiac surgeon).
-
Complex coronary artery disease
- Unprotected left main coronary artery
- Syntax score > 32 (in the absence of prior revascularization)
- Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within 30 days of screening evaluation.
- Need for emergency surgery for any reason.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03222128
Principal Investigator: | Martin B Leon, MD | Columbia University | |
Principal Investigator: | Craig Smith, MD | Columbia University |
Responsible Party: | Edwards Lifesciences |
ClinicalTrials.gov Identifier: | NCT03222128 |
Other Study ID Numbers: |
2010-12 PIIS3i |
First Posted: | July 19, 2017 Key Record Dates |
Results First Posted: | August 14, 2018 |
Last Update Posted: | November 30, 2023 |
Last Verified: | November 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
SAPIEN 3 Transfemoral Transapical Transaortic NovaFlex TAVI |
Aortic Stenosis THV Aortic Valve Transcatheter Heart Valve TAVR |
Aortic Valve Stenosis Aortic Valve Disease Heart Valve Diseases |
Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction |